Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone in metabolic syndrome and obesity
2010-022308-34Phase 2Terminated
- Sponsor
- Central Manchester University Hospitals NHS Foundation Trust
- Start
- Mar 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of eplerenone in cardiometabolic risk (CMR) and obesity, sponsored by Central Manchester University Hospitals NHS Foundation Trust. Primary endpoint: Effect of eplerenone on perivascular adipose tissue influence on subcutaneous small artery function. Started Mar 2011; status: terminated.
02
Drugs
eplerenone
03
Conditions
cardiometabolic risk (CMR)obesity
Beyond the preview
Go deeper on 2010-022308-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022308-34.